Six ahead-of-print studies in The Journal of Nuclear Medicine report PET tracking of radiolabeled trastuzumab deruxtecan in preclinical tumors, astatine-211 therapy against resistant uterine cancer in mice, 18F-DOPA PET associations in pancreatic neuroendocrine tumors, synaptic PET findings in cognitive decline, FAPI PET detection of potential gastric cancer metastases, and uPAR PET prediction of lung cancer recurrence.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.